loadpatents
Patent applications and USPTO patent grants for Schemainda; Isabel.The latest application filed is for "use of vitamin pp compounds".
Patent | Date |
---|---|
Use Of Vitamin Pp Compounds App 20100227896 - Biedermann; Elfi ;   et al. | 2010-09-09 |
Aryl-substituted pyridylalkane, alkene, and alkine carboxamides useful as cytostatic useful as cytostatic and immuosuppressive agents Grant 7,320,993 - Biedermann , et al. January 22, 2 | 2008-01-22 |
Cyclic imide-substituted pyridylalkane, alkene, alkine carboxamides useful as cytostatic and immunosuppressive agents Grant 7,192,967 - Biedermann , et al. March 20, 2 | 2007-03-20 |
Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides Grant 6,903,118 - Biedermann , et al. June 7, 2 | 2005-06-07 |
Piperadinyl-substituted pyridylalkane, alkene and alkine carboxamides Grant 6,593,344 - Biedermann , et al. July 15, 2 | 2003-07-15 |
Inhibitors of cellular niacinamide mononucleotide formation and their use in cancer therapy App 20020160968 - Biedermann, Elfi ;   et al. | 2002-10-31 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.